Chemotherapy for Glioma: Weighing the Options
- When treating low-grade gliomas, chemotherapy regiments PCV (Procarbazine, Lomustine, and Vincristine) and TMZ (Temozolomide) are the two main options if chemotherapy is recommended.
- PCV has a longer use history in low-grade glioma. However, it is a more intense regimen with higher rates of toxicity.
- TMZ is an oral regimen that may be easier to deliver and tolerate.
- The decision to use one regimen over the others will depend on several factors, including the patient’s risk of recurrence, overall health, and preference — as well as things like the side effect profile.
If your doctor does recommend chemotherapy, you have options. Typical chemotherapy regimens for low-grade gliomas include PCV (Procarbazine, Lomustine, and Vincristine) and TMZ (Temozolomide).
Read MoreHow Do I Know if I Am High-Risk?
Determining whether you are considered high-risk for glioma recurrence involves evaluating several different factors. Each of these factors contributes valuable information to the overall assessment.Several clinical features have traditionally been used to assess the likelihood of glioma recurrence.
These include:
- Age: Patients over the age of 40 tend to have a higher risk of glioma recurrence compared to younger patients.
- Incomplete Resection: If the tumor cannot be completely removed through surgery, the risk of recurrence increases.
- Glioma Location: Tumors located in certain areas of the brain may be harder to treat or remove completely, increasing recurrence risk.
- Size of Tumor: Larger tumors (> 6cm) are more challenging to treat effectively and are associated with a higher likelihood of recurrence.
- Significant Neurological Impairment: If the glioma has caused substantial neurological symptoms or deficits, this may indicate a more aggressive tumor and a higher recurrence risk.
- Molecular Features: In recent years, advancements in molecular biology have introduced new markers that help refine risk assessment for glioma recurrence. These include: IDH mutations, 1p/19q co-deletion status, TP53 mutations, and ATRX mutations.
Your care team will use a combination of these clinical and molecular features to determine your individual risk level and guide treatment recommendations.
Types of Chemotherapy
For patients with low-grade gliomas, two main chemotherapy regimens are commonly considered: PCV (Procarbazine, Lomustine, and Vincristine) and TMZ (Temozolomide).
The PCV regimen is a well-established treatment option for low-grade gliomas. Research has demonstrated that PCV can improve both overall survival and progression-free survival.
However, it is an intense regimen that requires:
- Regular IV Infusions (which means frequent visits to the clinic for intravenous administration)
- Blood Count Monitoring (regular blood tests to monitor for side effects such as low blood counts)
Possible side effects include:
- Low blood counts, increasing the risk of infections and fatigue
- Fatigue and general weakness
- Increased risk of developing secondary cancers
“PCV is a very difficult treatment regimen for patients to tolerate,” Dr. Ghiaseddin explains. “Frequently, patients forego the vincristine, or the ‘V’ of the PCV regimen.”
Despite these challenges, patients with certain molecular markers, such as the 1p/19q co-deletion, often respond particularly well to PCV.
Temozolomide (TMZ) is another chemotherapy option that has been widely used, particularly for high-grade gliomas. However, it has also found a role in treating low-grade gliomas, especially for patients who may not tolerate the more intensive PCV regimen.
Advantages of TMZ include:
- Oral Administration: TMZ is taken as a pill, making it more convenient than PCV.
- High Brain Penetration: TMZ effectively crosses the blood-brain barrier, allowing it to target brain tumors directly.
Potential side effects include:
- Nausea and vomiting, which can often be managed with anti-nausea medications
- Low blood counts, leading to an increased risk of infections and fatigue
- Development of opportunistic infections, such as Pneumocystis jirovecii pneumonia (PJP). To prevent this, patients on TMZ are often prescribed prophylactic antibiotics.
Patients with the MGMT promoter methylation have shown particularly favorable responses to TMZ, making this an important molecular marker for treatment planning.
PCV vs. TMZ: Which Treatment is Best for Me?
It is unclear whether one regimen is definitively superior to the other for all patients.
“There are early trials that suggest PCV may be the best option for some patients, but there has never been a head-to-head trial comparing temozolomide to PCV,” Dr. Ghiaseddin explains.
The decision to choose one regimen over the other depends on several factors, including:
- Risk of Recurrence: Patients with higher-risk tumors may benefit from the more aggressive PCV regimen.
- Performance Status: Your overall health and ability to tolerate treatment side effects are crucial considerations.
- Side Effect Tolerance: PCV is associated with more intense side effects, which may make TMZ a better option for some patients.
- Quality of Life: For many patients, preserving overall quality of life is a priority, and this may influence treatment choices.
Questions to Ask Your Doctor
If you or a loved one is facing treatment decisions for glioma, it’s important to have open and honest conversations with your care team. Consider asking the following questions:
- Based on my clinical and molecular features, what is my risk of recurrence?
- What are the potential benefits and risks of PCV and TMZ in my case?
- How will treatment impact my quality of life, both during and after chemotherapy?
- Are there other treatment options, such as radiation therapy, that should be considered alongside chemotherapy?
- What kind of follow-up care and monitoring will I need during treatment?
Learn more about SurvivorNet's rigorous medical review process.